Adult-onset Still's disease: Advances in the treatment

Best Practice and Research: Clinical Rheumatology

Volumn 30, Issue 2, 2016, Pages 222-238

  Castañeda, Santos ^a,b   Blanco, Ricardo ^c   González Gay, Miguel A ^c,d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Adult onset Still's disease; Anti IL 6 receptor antibody tocilizumab; Biologic agents; DMARDs; IL 1 receptor antagonist anakinra; Macrophage activation syndrome; TNF inhibitors

Indexed keywords

BIOLOGICAL PRODUCT; CHEMOKINE; CORTICOSTEROID; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FERRITIN; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

ADAPTIVE IMMUNITY; ADULT ONSET STILL DISEASE; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; FERRITIN BLOOD LEVEL; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ADULT; PATHOPHYSIOLOGY; STILL'S DISEASE, ADULT-ONSET;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; HUMANS; STILL'S DISEASE, ADULT-ONSET;

EID: 84996866082     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.08.003     Document Type: Review

References (100)

1. [1] Bywaters, E.G., Still's disease in the adult. Ann Rheum Dis 30 (1971), 121–133.
2. [2] Still, G.F., On a form of chronic joint disease in children. Med Chir Trans 80 (1897), 47–60.
3. [3] Magadur-Joly, G., Billaud, E., Barrier, J.H., et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 54 (1995), 587–590.
4. [4] Wakai, K., Ohta, A., Tamakoshi, A., et al. Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 7 (1997), 221–225.
5. [5] Evensen, K.J., Nossent, H.C., Epidemiology and outcome of adult-onset Still's disease in Northern Norway. Scand J Rheumatol 35 (2006), 48–51.
6. [6] Sampalis, J.S., Esdaile, J.M., Medsger, T.A., et al. A controlled study of the long-term prognosis of adult Still's disease. Am J Med 98 (1995), 384–388.
7. [7] Cagatay, Y., Gul, A., Cagatay, A., et al. Adult-onset Still's disease. Int J Clin Pract 63 (2009), 1050–1055.
8. Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., Sève, P., Adult-onset Still's disease. Autoimmun Rev 13 (2014), 708–722.
9. Maria, A.T., Le Quellec, A., Jorgensen, C., et al. Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13 (2014), 1149–1159.
10. [10] Gerfaud-Valentin, M., Sève, P., Hot, A., et al. Pathophysiology, subtypes, and treatments of adult-onset Still's disease: an update. Rev Med Interne 36 (2015), 319–327 [Article in French].
11. [11] Kádár, J., Petrovicz, E., Adult-onset Still's disease. Best Pract Res Clin Rheumatol 18 (2004), 663–676.
12. [12] Iliou, C., Papagoras, C., Tsifetaki, N., et al. Adult-onset Still's disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol 31 (2013), 47–52.
13. [13] Fautrel, B., Le Moël, G., Saint-Marcoux, B., et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 28 (2001), 322–329.
14. [14] Vignes, S., Le Moël, G., Fautrel, B., et al. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still's disease. Ann Rheum Dis 59 (2000), 347–350.
15. [15] Efthimiou, P., Kadavath, S., Mehta, B., Life-threatening complications of adult-onset Still's disease. Clin Rheumatol 33 (2014), 305–314.
16. Yamaguchi, M.1, Ohta, A., Tsunematsu, T., et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 19 (1992), 424–430.
17. Fautrel, B., Zing, E., Golmard, J.L., et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore) 81 (2002), 194–200.
18. [18] Chen, D.Y., Lin, C.C., Chen, Y.M., et al. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease. Arthritis Res Ther, 15, 2013, R39.
19. [19] Hoshino, T., Ohta, A., Yang, D., et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 25 (1998), 396–398.
20. [20] Matsui, K., Tsuchida, T., Hiroishi, K., et al. High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still's disease. Rheumatology (Oxford) 38 (1999), 477–478.
21. [21] Zou, Y.Q., Lu, L.J., Li, S.J., et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease. Clin Biochem 41 (2008), 519–524.
22. [22] Chen, D.Y., Lan, J.L., Lin, F.J., Hsieh, T.Y., Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still's disease. Arthritis Rheum 53 (2005), 320–327.
23. [23] Lee, S.J., Cho, Y.N., Kim, T.J., et al. Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum 64 (2012), 2868–2877.
24. [24] Park, J.H., Kim, H.S., Lee, J.S., et al. Natural killer cell cytolytic function in Korean patients with adult-onset Still's disease. J Rheumatol 39 (2012), 2000–2007.
25. [25] Wulffraat, N.M., Rijkers, G.T., Elst, E., et al. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 42 (2003), 375–379.
26. [26] Chen, D.Y., Lan, J.L., Lin, F.J., et al. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 63 (2004), 1300–1306.
27. [27] Chen, D.Y., Chen, Y.M., Chen, H.H., et al. The associations of circulating CD4+CD25high regulatory T cells and TGF-β with disease activity and clinical course in patients with adult-onset Still's disease. Connect Tissue Res 51 (2010), 370–377.
28. [28] Chen, D.Y., Lan, J.L., Lin, F.J., Hsieh, T.Y., Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 31 (2004), 2189–2198.
29. [29] Pascual, V., Allantaz, F., Arce, E., et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201 (2005), 1479–1486.
30. [30] Scheinberg, M.A., Chapira, E., Fernandes, M.L., Hubscher, O., Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol 14 (1996), 653–655.
31. Puéchal, X., DeBandt, M., Berthelot, J.M., et al., Club Rhumatismes Et Inflammation. Tocilizumab in refractory adult Still's disease. Arthritis Care Res (Hoboken) 63 (2011), 155–159.
32. Ortiz-Sanjuán, F., Blanco, R., Calvo-Rio, V., et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 66 (2014), 1659–1665.
33. [33] Maruyama, J., Inokuma, S., Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 37 (2010), 967–973.
34. [34] Sugiura, T., Kawaguchi, Y., Harigai, M., et al. Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 3 (2002), 394–399.
35. [35] Choi, J.H., Suh, C.H., Lee, Y.M., et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 30 (2003), 2422–2427.
36. [36] Pouchot, J., Sampalis, J.S., Beaudet, F., et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70 (1991), 118–136.
37. [37] Kim, Y.J., Koo, B.S., Kim, Y.G., et al. Clinical features and prognosis in 82 patients with adult-onset Still's disease. Clin Exp Rheumatol 32 (2014), 28–33.
38. [38] Colina, M., Zucchini, W., Ciancio, G., et al. The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum 41 (2011), 279–285.
39. [39] Fautrel, B., Borget, C., Rozenberg, S., et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 26 (1999), 373–378.
40. [40] Al-Homood, I.A., Biologic treatments for adult-onset Still's disease. Rheumatology (Oxford) 53 (2014), 32–38.
41. Gerfaud-Valentin, M., Maucort-Boulch, D., Hot, A., et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 93 (2014), 91–99.
42. [42] Franchini, S., Dagna, L., Salvo, F., et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum 62 (2010), 2530–2535.
43. [43] Cavagna, L., Caporali, R., Epis, O., et al. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 19 (2001), 329–332.
44. [44] Kraetsch, H.G., Antoni, C., Kalden, J.R., Manger, B., Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis, 60(Suppl. 3), 2001 iii55-7.
45. [45] Kokkinos, A., Iliopoulos, A., Greka, P., et al. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 23 (2004), 45–49.
46. [46] Caramaschi, P., Biasi, D., Carletto, A., Bambara, L.M., A case of adult onset Still's disease treated with infliximab. Clin Exp Rheumatol, 20, 2002, 113.
47. [47] Olivieri, I., de Stefano, G., Padula, A., et al. Infliximab in a case of early adult-onset Still's disease. Clin Rheumatol 22 (2003), 369–370.
48. [48] Husni, M.E., Maier, A.L., Mease, P.J., et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 46 (2002), 1171–1176.
49. [49] Felson, D.T., Anderson, J.J., Boers, M., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995), 727–735.
50. [50] Serratrice, J., Granel, B., Disdier, P., et al. Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still's disease. Am J Med 115 (2003), 589–590.
51. [51] Yang, D.H., Chang, D.M., Lai, J.H., et al. Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure. Rheumatol Int 29 (2008), 95–98.
52. [52] Lovell, D.J., Giannini, E.H., Reiff, A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342 (2000), 763–769.
53. Fautrel, B., Sibilia, J., Mariette, X., Combe, B., Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 64 (2005), 262–266.
54. [54] Benucci, M., Li, G.F., Del Rosso, A., Manfredi, M., Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report. Clin Exp Rheumatol, 23, 2005, 733.
55. [55] Rech, J., Ronneberger, M., Englbrecht, M., et al. Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis 70 (2011), 390–392.
56. [56] Kaneko, K., Kaburaki, M., Muraoka, S., et al. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis 13 (2010), e67–69.
57. [57] Agarwal, S., Moodley, J., Ajani Goel, G., et al. A rare trigger for macrophage activation syndrome. Rheumatol Int 31 (2011), 405–407.
58. [58] Aikawa, N.E., Ribeiro, A.C., Saad, C.G., et al. Is anti-TNF switching in refractory Still's disease safe and effective?. Clin Rheumatol 30 (2011), 1129–1134.
59. [59] Koné-Paut, I., Piram, M., Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes: what did we learn?. Autoimmun Rev 12 (2012), 77–80.
60. [60] Hoffman, H.M., Therapy of autoinflammatory syndromes. J Allergy Clin Immunol 124 (2009), 1129–1138.
61. [61] Rudinskaya, A., Trock, D.H., Successful treatment of a patient with refractory adult-onset still disease with anakinra. J Clin Rheumatol 9 (2003), 330–332.
62. [62] Vasques Godinho, F.M., Parreira Santos, M.J., Canas da Silva, J., Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 64 (2005), 647–648.
63. [63] Fitzgerald, A.A., Leclercq, S.A., Yan, A., et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52 (2005), 1794–1803.
64. Kalliolias, G.D., Georgiou, P.E., Antonopoulos, I.A., et al. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66 (2007), 842–843.
65. [65] Kötter, I., Wacker, A., Koch, S., et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 37 (2007), 189–197.
66. [66] Nordström, D., Knight, A., Luukkainen, R., et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol 39 (2012), 2008–2011.
67. [67] El Karoui, K., Karras, A., Lebrun, G., et al. Thrombotic microangiopathy and purtscher-like retinopathy associated with adult-onset Still's disease: a role for glomerular vascular endothelial growth factor?. Arthritis Rheum 61 (2009), 1609–1613.
68. [68] Lequerré, T., Quartier, P., Rosellini, D., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67 (2008), 302–308.
69. [69] Giampietro, C., Ridene, M., Lequerre, T., et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken) 65 (2013), 822–826.
70. [70] Nigrovic, P.A., Mannion, M., Prince, F.H., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63 (2011), 545–555.
71. [71] Laskari, K., Tzioufas, A.G., Moutsopoulos, H.M., Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther, 13, 2011, R91.
72. Ortiz-Sanjuán, F., Blanco, R., Riancho-Zarrabeitia, L., et al. Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review. Medicine (Baltimore), 94, 2015, e1554.
73. [73] Gattorno, M., Piccini, A., Lasigliè, D., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58 (2008), 1505–1515.
74. [74] Guignard, S., Dien, G., Dougados, M., Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 25 (2007), 758–759.
75. [75] Naumann, L., Feist, E., Natusch, A., et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 69 (2010), 466–467.
76. [76] Maier, J., Birkenfeld, G., Pfirstinger, J., et al. Effective treatment of steroid refractory adult-onset Still's disease with anakinra. J Rheumatol 35 (2008), 939–941.
77. [77] Lachmann, H.J., Kone-Paut, I., Kuemmerle-Deschner, J.B., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360 (2009), 2416–2425.
78. [78] Kontzias, A., Efthimiou, P., The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum 42 (2012), 201–205.
79. [79] Petryna, O., Cush, J.J., Efthimiou, P., IL-1 Trap rilonacept in refractory adult onset Still's disease. Ann Rheum Dis 71 (2012), 2056–2057.
80. [80] Iwamoto, M., Nara, H., Hirata, D., et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 46 (2002), 3388–3389.
81. [81] De Bandt, M., Saint-Marcoux, B., Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 68 (2009), 153–154.
82. [82] Sakai, R., Nagasawa, H., Nishi, E., et al. Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol 31 (2012), 569–574.
83. [83] Suematsu, R., Ohta, A., Matsuura, E., et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol 22 (2012), 712–719.
84. [84] Cipriani, P., Ruscitti, P., Carubbi, F., et al. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol 33 (2014), 49–55.
85. [85] Elkayam, O., Jiries, N., Dranitzki, Z., et al. Tocilizumab in adult-onset Still's disease: the Israeli experience. J Rheumatol 41 (2014), 244–247.
86. [86] De Benedetti, F., Brunner, H.I., Ruperto, N., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2385–2395.
87. [87] Nishina, N., Kaneko, Y., Kameda, H., Takeuchi, T., The effect of tocilizumab on preventing relapses in adult-onset Still's disease: a retrospective, single-center study. Mod Rheumatol 25 (2015), 401–404.
88. [88] Kobayashi, M., Takahashi, Y., Yamashita, H., et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21 (2011), 92–96.
89. [89] Permal, S., Wechsler, B., Cabane, J., et al. Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne 16 (1995), 250–254 [Article in French].
90. [90] Kulke, R., Koeppel, M., Hey, D., Treatment of adult Still's disease with intravenous immunoglobulin. Lancet, 347(8997), 1996, 337.
91. [91] Liozon, E., Ly, K., Aubard, Y., et al. Intravenous immunoglobulins for adult Still's disease and pregnancy. Rheumatology (Oxford) 38 (1999), 1024–1025.
92. [92] Vignes, S., Wechsler, B., Amoura, Z., et al. Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 16 (1998), 295–298.
93. [93] Mahmud, T., Hughes, G.R., Intravenous immunoglobulin in the treatment of refractory adult Still's disease. J Rheumatol 26 (1999), 2067–2068.
94. [94] Bennett, A.N., Peterson, P., Sangle, S., et al. Adult onset Still's disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulins and mycophenolate mofetil. Rheumatology (Oxford) 43 (2004), 795–799.
95. [95] Prieur, A.M., Intravenous immunoglobulins in Still's disease: still controversial, still unproven. J Rheumatol 23 (1996), 797–800.
96. [96] Asherson, R.A., Pascoe, L., Adult onset Still's disease: response to Enbrel. Ann Rheum Dis 61 (2002), 859–860.
97. [97] Ahmadi-Simab, K., Lamprecht, P., Jankowiak, C., Gross, W.L., Successful treatment of refractory adult onset Still's disease with rituximab. Ann Rheum Dis 65 (2006), 1117–1118.
98. [98] Bartoloni, E., Alunno, A., Luccioli, F., et al. Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody. Clin Exp Rheumatol 27 (2009), 888–889.
99. [99] Ostrowski, R.A., Tehrani, R., Kadanoff, R., Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol 17 (2011), 315–317.
100. [100] Quartuccio, L., Maset, M., De Vita, S., Efficacy of abatacept in a refractory case of adult-onset Still's disease. Clin Exp Rheumatol 28 (2010), 265–267.